WEST PHARMACEUTICAL SERVICES, INC. financials

  1. Home
  2. Financials
  3. WST
WST CIK 0000105770

Source: EDGAR filings · Built 2026-06-02T04:25:39Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 467.80M 253.10M 414.40M 439.40M 330.60M 298.10M
EBITDA 756.30M 725.30M 813.30M 854.60M 874.60M 516.00M
Working Capital 1.32B 987.70M 1.26B 1.40B 1.15B 870.30M
Net Debt -465.10M -179.30M -544.90M -576.40M -437.30M -289.80M
Gross Margin 35.91% 34.51% 38.28% 39.36% 41.52% 35.76%
Operating Margin 19.03% 19.70% 22.92% 25.43% 26.57% 18.95%
Net Margin 16.06% 17.03% 20.12% 20.30% 23.37% 16.13%
Return on Equity (ROE) 15.54% 18.37% 20.60% 21.82% 28.34% 18.67%
Return on Assets (ROA) 11.56% 13.52% 15.50% 16.20% 19.97% 12.39%
Current Ratio 3.02× 2.79× 2.88× 3.70× 2.93× 2.73×
Debt-to-Equity 0.10× 0.11× 0.11× 0.12× 0.14× 0.18×
Effective Tax Rate 20.24% 18.36% 17.52% 16.87% 14.31% 18.07%
Cash Conversion Ratio 1.53× 1.33× 1.31× 1.24× 0.88× 1.36×
Accruals Ratio -0.06× -0.04× -0.05× -0.04× 0.02× -0.05×
SBC % of Revenue 0.77% 0.65% 0.79% 0.82% 1.32% 1.58%
CapEx Coverage 2.63× 1.63× 2.14× 2.54× 2.30× 2.71×
Free Cash Flow Per Share $6.43 $3.43 $5.50 $5.80 $4.33 $3.93

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 40.52× 48.96× 44.69× 30.45× 54.10× 61.99×
P/FCF 42.76× 95.38× 63.98× 40.60× 108.24× 72.04×
FCF Yield 2.34% 1.05% 1.56% 2.46% 0.92% 1.39%
EV / EBITDA 25.58× 32.40× 31.15× 19.73× 39.29× 40.07×
P/S 6.44× 8.19× 8.77× 6.04× 12.29× 9.77×
P/B 6.24× 8.83× 8.98× 6.50× 14.90× 11.30×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 3.07B 2.89B 2.95B 2.89B 2.83B 2.15B
Revenues — — — 2.89B 2.83B 2.15B
Cost of Goods and Services Sold 1.97B 1.89B 1.82B 1.75B 1.66B 1.38B
Gross Profit 1.10B 998.50M 1.13B 1.14B 1.18B 767.80M
Research and Development Expense 74.30M 69.10M 68.40M 58.50M 52.80M 46.90M
Selling, General and Administrative Expense 393.60M 338.50M 353.40M 316.90M 362.80M 302.00M
Operating Income (Loss) 584.90M 569.90M 676.00M 734.00M 752.30M 406.90M
Income Tax Expense (Benefit) 121.60M 107.50M 122.30M 114.70M 107.20M 72.50M
Net Income (Loss) Attributable to Parent 493.70M 492.70M 593.40M 585.90M 661.80M 346.20M
Earnings Per Share, Basic $6.83 $6.75 $7.98 $7.87 $8.89 $4.68
Weighted Average Number of Shares Outstanding, Basic 72.30M 73.00M 74.30M 74.40M 74.40M 73.90M
Earnings Per Share, Diluted $6.79 $6.69 $7.88 $7.73 $8.67 $4.57
Weighted Average Number of Shares Outstanding, Diluted 72.70M 73.70M 75.30M 75.80M 76.30M 75.80M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 791.30M 484.60M 853.90M 894.30M 762.60M 615.50M
Assets, Current 1.98B 1.54B 1.94B 1.92B 1.74B 1.37B
Assets 4.27B 3.64B 3.83B 3.62B 3.31B 2.79B
Long-term Debt 202.80M 202.60M 206.80M 208.90M 253.00M 255.20M
Liabilities, Current 654.90M 550.40M 671.80M 519.00M 594.10M 503.40M
Long-term Debt, Excluding Current Maturities 202.80M 202.60M 72.80M 206.70M 208.80M 252.90M
Liabilities 1.09B 961.10M 948.50M 931.90M 978.40M 939.30M
Stockholders' Equity Attributable to Parent 3.18B 2.68B 2.88B 2.68B 2.34B 1.85B
Common Stock, Shares, Outstanding 72.00M 72.30M 73.50M 74.10M 74.20M 74.00M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 754.80M 653.40M 776.50M 724.00M 584.00M 472.50M
Payments to Acquire Property, Plant, and Equipment 285.90M 377.00M 362.00M 284.60M 253.40M 174.40M
Net Cash Provided by (Used in) Investing Activities -285.90M -378.70M -368.70M -288.20M -253.10M -179.50M
Payments for Repurchase of Common Stock 134.00M 560.90M 438.30M 202.80M 137.10M 115.50M
Net Cash Provided by (Used in) Financing Activities -185.10M -622.60M -459.60M -293.60M -168.10M -137.10M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (WST CIK 0000105770), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

BYND

BEYOND MEAT, INC.

KELYA

KELLY SERVICES, INC.

SLS

SELLAS Life Sciences Group, Inc.